# US 2015/0031659 A1 · 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0031659 A1
- Document ID: US20150031659A1
- Status: Published application
- Kind: A1
- Application number: 14/505,442
- Filed: 2014-10-02
- Published: 2015-01-29
- Earliest claimed: 2012-03-30
- Assignees: Cubist Pharmaceuticals, Inc.
- Applicants: Cubist Pharmaceuticals, Inc.
- Inventors: Yu Gui Gu; Yong He; Ning Yin; Dylan C. Alexander; Jason B. Cross; Chester A. Metcalf, III; Robert Busch
- Web page: https://patentgrep.com/patent/US20150031659A1

## CPC

- A61K 31/546: containing further heterocyclic rings, e.g. cephalothin
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 31/545: Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: [IMAGE cpc-sch-A61K-0953.gif] , e.g. cephalosporins, {cefaclor, or cephalexine}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/04: Antibacterial agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 471/08: Bridged systems
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.

## Claims

### Claim at position 1

1-21. (canceled)

### Claim 22

A pharmaceutical composition comprising ceftolozane or a pharmaceutically acceptable salt thereof and a compound of the formula:
or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 22)

A method of treating or preventing a bacterial infection comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition according to claim 22.

### Claim 24 (depends on 23)

The method of claim 23 wherein the bacterial infection is caused by bacteria that produce a class A, class C or class D β-actamase.

### Claim 25 (depends on 24)

The method of claim 24 wherein the bacterial infection is caused by bacteria selected from Acinetobacter spp., Acinetobacter baumannii, Citrobacter spp., Escherichia spp., Escherichia coli, Haemophilus influenzae, Morganella morganii, Pseudomonas aeruginosa, Klebsiella spp., Klebsiella pneumoniae, Enterobacter spp., Enterobacter cloacae, Enterobacter aerogenes, Pasteurella spp., Proteus spp., Proteus mirabilis, Serratia spp., Serratia marcescens, and Providencia spp.

### Claim 26 (depends on 24)

The method of claim 24 wherein the bacterial infection is caused by bacteria that produce a KPC-2 or KPC-3 β-lactamase.

### Claim 27 (depends on 24)

The method of claim 24 wherein the bacterial infection is caused by bacteria that produce an OXA-15 β-lactamase.

### Claim 28 (depends on 23)

The method of claim 23 wherein the bacterial infection is caused by β-actam resistant bacteria.

### Claim 29 (depends on 23)

The method of claim 23 wherein the ceftolozane and the compound of formula (I) are administered together in a single composition.
